Comparison of serum and plasma microRNA expression levels in patients with germ cell tumours
Fady Baky
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Search for more papers by this authorRichard S. Matulewicz
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Search for more papers by this authorAndrea Knezevic
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Search for more papers by this authorJahwa Hossain
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Search for more papers by this authorBrandon Williams
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Search for more papers by this authorAnna Lee
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Search for more papers by this authorJoel Sheinfeld
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Search for more papers by this authorNicole Liso
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Search for more papers by this authorRachel So
Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Search for more papers by this authorAlisa Valentino
Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Search for more papers by this authorFei Ye
Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Search for more papers by this authorCorresponding Author
Samuel A. Funt
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Department of Medicine, Weill Cornell Medical College, New York, NY, USA
Correspondence: Samuel A. Funt, 300 East 66th St, Rm 1255, New York, NY 10011, USA.
e-mail: [email protected]
Search for more papers by this authorDarren R. Feldman
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Department of Medicine, Weill Cornell Medical College, New York, NY, USA
Search for more papers by this authorFady Baky
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Search for more papers by this authorRichard S. Matulewicz
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Search for more papers by this authorAndrea Knezevic
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Search for more papers by this authorJahwa Hossain
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Search for more papers by this authorBrandon Williams
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Search for more papers by this authorAnna Lee
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Search for more papers by this authorJoel Sheinfeld
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Search for more papers by this authorNicole Liso
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Search for more papers by this authorRachel So
Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Search for more papers by this authorAlisa Valentino
Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Search for more papers by this authorFei Ye
Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Search for more papers by this authorCorresponding Author
Samuel A. Funt
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Department of Medicine, Weill Cornell Medical College, New York, NY, USA
Correspondence: Samuel A. Funt, 300 East 66th St, Rm 1255, New York, NY 10011, USA.
e-mail: [email protected]
Search for more papers by this authorDarren R. Feldman
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Department of Medicine, Weill Cornell Medical College, New York, NY, USA
Search for more papers by this authorF.B., R.S.M., S.A.F. and D.R.F. contributed equally as first and senior authors, respectively.
Supporting Information
| Filename | Description |
|---|---|
| bju16644-sup-0001-TablesS1-S4.docxWord 2007 document , 28.8 KB | Table S1. Patient and disease characteristics for cohort of patients on surveillance (n = 15) and those with disease prior to treatment (n = 15). Table S2. Agreement of serum and plasma combined miR-371a-3p and miR-372-3p assay results. Table S3. Agreement of serum and plasma miRNA-371a-3p and miRNA-372-3p results, individually. Table S4. Serum and plasma combined miRNA 371a-3p and 372-3p result for detection of viable GCT. |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
References
- 1Leão R, Albersen M, Looijenga LHJ et al. Circulating microRNAs, the next-generation serum biomarkers in testicular germ cell tumours: a systematic review. Eur Urol 2021; 80: 456–466
- 2Ye F, Feldman DR, Valentino A et al. Analytical validation and performance characteristics of molecular serum biomarkers, miR-371a-3p and miR-372-3p, for male germ cell tumors, in a clinical laboratory setting. J Mol Diagn 2022; 24: 867–877
- 3Matulewicz RS, Baky F, Knezevic A et al. Perioperative serum microRNA 371a-3p and 372-3p levels in patients with clinically localized testicular masses. Eur Urol Open Sci 2024; 68: 1–9
- 4Binderup HG, Madsen JS, Heegaard NHH, Houlind K, Andersen RF, Brasen CL. Quantification of microRNA levels in plasma – impact of preanalytical and analytical conditions. PLoS One 2018; 13: e0201069
- 5Mørup N, Rajpert-De Meyts E, Juul A, Daugaard G, Almstrup K. Evaluation of circulating miRNA biomarkers of testicular germ cell tumors during therapy and follow-up-a Copenhagen experience. Cancer 2020; 12: 759
10.3390/cancers12030759 Google Scholar
- 6Lobo J, Gillis AJM, van den Berg A et al. Identification and validation model for informative liquid biopsy-based microRNA biomarkers: insights from germ cell tumor in vitro, in vivo and patient-derived data. Cells 2019; 8: E1637
- 7Lafin JT, Scarpini CG, Amini A et al. Refining the serum miR-371a-3p test for viable germ cell tumor detection. Sci Rep 2023; 13: 10558
